Breaking News
November 21, 2017 - Seven body organs you can live without
November 21, 2017 - Simple test could help predict best treatment for cystic fibrosis patients
November 21, 2017 - Diabetes patients’ immune system can regulate insulin production
November 21, 2017 - Simple mirror technique boosts the performance of diSPIM, study says
November 21, 2017 - FDA raids Florida stores that consumers use to buy drugs from Canada
November 21, 2017 - FDA Alert: Limbrel Capsules by Primus Pharmaceuticals: FDA Advisory
November 21, 2017 - Exploring the genetics of glaucoma and retinal development
November 21, 2017 - Study finds sensors to detect biomarkers
November 21, 2017 - Researchers develop simple test to predict T2D remission after bariatric surgery
November 21, 2017 - Penn researchers find evidence of new malaria species in wild bonobos
November 21, 2017 - Review examines effectiveness of lipid-based products to treat dry eye disease
November 21, 2017 - Pioneering research project aims to develop better diagnostic tests for NAFLD
November 21, 2017 - The Best and Worst Ways to Say ‘I Love You’
November 21, 2017 - Even Partial Breast-Feeding for First Few Months Lowers SIDS Risk: MedlinePlus Health News
November 21, 2017 - Researchers identify protein that plays key role in diabetic blindness
November 21, 2017 - Sensors for identifying biomarkers could help detect myriad of diseases at early stages
November 21, 2017 - ‘Chemo brain’ may start as tumors form and develop, suggests study
November 21, 2017 - Scientists develop new method to study Creutzfeldt-Jakob disease in the lab
November 21, 2017 - Researchers identify previously unknown breast cell types
November 21, 2017 - Probing living cells with AFM
November 21, 2017 - Streamlined method for using CGM helps patients with diabetes maintain safe, stable glucose levels
November 21, 2017 - Even Advanced Breast Cancer Patients Gain From Exercise: MedlinePlus Health News
November 21, 2017 - Study in mice finds dietary levels of genistein may adversely affect female fertility
November 21, 2017 - Disordered eating has detrimental effects to long-term health of young adults, study finds
November 21, 2017 - Babies know more than we think they do find researchers
November 21, 2017 - New technique may reveal clues about role of centromeres in Down syndrome, other birth defects
November 21, 2017 - IUD May Lower Cervical Cancer Risk: MedlinePlus Health News
November 21, 2017 - U.S. preemie birth rates rise two years in a row
November 21, 2017 - Heart rate variability measured by electrocardiogram can help differentiate bipolar from major depression
November 21, 2017 - $10 million gift creates new center at Northwestern University to study effects of environment on genes
November 21, 2017 - Uncontrolled lung diseases could lead to costly A&E visits and hospital stays
November 21, 2017 - New study explores patients’ and family members’ views on overlapping surgeries
November 21, 2017 - KNAUER celebrates 55th anniversary and awards science prize
November 21, 2017 - Researchers find new way to boost cancer-destroying ability of T-cells
November 21, 2017 - Maintaining adequate vitamin D may help prevent onset of inflammatory diseases
November 21, 2017 - What NPs Can Do in the Opioid Crisis
November 21, 2017 - Gun Injuries Getting More Severe, Experts Say: MedlinePlus Health News
November 21, 2017 - That music playing in your head is a real conundrum for scientists
November 21, 2017 - Researcher awarded $1.5 million to study role of tumor necrosis factor in IBD
November 21, 2017 - Digital pills can help track opioid use patterns
November 21, 2017 - UZH leads Europe’s largest research on aging
November 21, 2017 - Experts endorse recommendations for restrictive blood transfusions
November 21, 2017 - New Hemophilia A Treatment, Hemlibra (Emicizumab-kxwh), Stems Bleeding Episodes
November 21, 2017 - Shining a light on the nervous system to thwart disease
November 21, 2017 - Use of Prostate Health Index cuts down need for uncomfortable biopsies
November 21, 2017 - Drugstore pain pills as effective as opioids in ER patients
November 21, 2017 - Experts explain why lead found in fidget spinners is no idle threat
November 21, 2017 - Over-the-counter decongestant found to be effective inhibitor of tumor stroma
November 21, 2017 - Anticholinergic Cognitive Burden Scale shows dose-response relationship with adverse outcomes
November 21, 2017 - Non-vitamin K antagonist oral anticoagulants linked to reduced kidney risks
November 21, 2017 - New technique holds promise to screen cancer cells for drug susceptibility
November 21, 2017 - AstraZeneca wins US approval for lymphoma drug
November 21, 2017 - Mother’s diet can protect nursing newborns against food allergies, research shows
November 21, 2017 - Cystic fibrosis patients have more good and bad bacteria in their lungs, study finds
November 21, 2017 - Patient-centered medical home model effective at improving chronic disease outcomes
November 21, 2017 - Enterovirus vaccine protects against virus-induced diabetes in mouse model
November 20, 2017 - First-of-its-kind study combines smoking cessation with personalized medicine
November 20, 2017 - FDA Approves Sutent (sunitinib malate) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
November 20, 2017 - Researchers produce the first draft cell atlas of the small intestine
November 20, 2017 - Study explores feasibility of mainstreaming genetic counseling for ovarian cancer
November 20, 2017 - AAP and The Obesity Society jointly address weight stigma in childhood obesity
November 20, 2017 - Researchers identify three specific molecules that accurately indicate pre-diabetes
November 20, 2017 - Study estimates health care costs, injuries, and deaths due to motorcycle accidents
November 20, 2017 - Face It: Drinking, Smoking Takes Toll on Looks
November 20, 2017 - Women have lower tolerance to alcohol following gastric sleeve surgery, study finds
November 20, 2017 - Salt, inflammation and hypertension
November 20, 2017 - Electrochemistry method provides easy access to important classes of compounds
November 20, 2017 - Cancer drugs may offer new way to control high blood pressure
November 20, 2017 - Small molecules in saliva may offer clues to diagnose and predict duration of concussions
November 20, 2017 - New poll demonstrates challenge of finding childcare options that meet parent’s safety criteria
November 20, 2017 - Canadians root for an underdog U.S. health policy idea
November 20, 2017 - KAIST researchers identify principles of gene network for colon tumorigenesis
November 20, 2017 - Pregnant mother in a coma wakes three months after delivery
November 20, 2017 - VTT researcher develops disposable optical test substrate for microbial detection
November 20, 2017 - Benzodiazepines linked to increased risk of death among Alzheimer’s disease patients
November 20, 2017 - Women are advised that sleeping on their side could reduce stillbirth risk
November 20, 2017 - The skinny on lipid immunology
November 20, 2017 - Study sheds light on changes in young people’s sexual practices
November 20, 2017 - Study highlights need for early identification, treatment of PTSD in cancer survivors
November 20, 2017 - FDA approves remote programming feature for Nucleus Cochlear Implant System via telemedicine
Kura Oncology Lead Candidate Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC Update

Kura Oncology Lead Candidate Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC Update

image_pdfDownload PDFimage_print

SAN DIEGO, Oct. 27, 2017 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today presented updated preliminary results from its Phase 2 open-label trial of tipifarnib, a farnesyltransferase inhibitor, in patients with head and neck squamous cell carcinomas (HNSCC) with HRAS mutations.

The results were featured in a late-breaking, oral presentation by Dr. Alan Ho of Memorial Sloan Kettering Cancer Center at the Spotlight on Proffered Papers Session 1 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place today in Philadelphia.

Four out of six evaluable HRAS mutant HNSCC patients enrolled in the study achieved a confirmed partial response, as defined by standard RECIST criteria. In addition, as of the data cutoff date of October 4, 2017, four HRAS mutant HNSCC patients remained on study in cycles 21, 7, 5 and 3. The patients in cycles 21, 7 and 5 had all experienced partial responses while the patient in cycle 3 experienced stable disease as of the first response assessment in cycle 2. One HRAS mutant HNSCC patient with a confirmed partial response remained on study through cycle 20 and withdrew in cycle 21 with progressive disease. Another HRAS mutant HNSCC patient experienced a best response assessment of stable disease and withdrew from the study in cycle 8.

Tipifarnib has demonstrated clinical activity in previously treated patients, including those who have progressed on chemotherapy with or without cetuximab or immune therapy. The majority of adverse events reported by the investigators have been mild to moderate and are consistent with the adverse event profile previously reported for tipifarnib.

“The responses, durability and safety data with tipifarnib clearly suggest this is an important drug candidate for patients with HRAS mutant head and neck cancers,” said Alan Ho, M.D., Ph.D., of Memorial Sloan Kettering Cancer Center and presenter of the tipifarnib oral presentation. “We are excited to continue to follow these patients and treat additional HRAS mutant patients in the ongoing Phase 2 trial.”

“The consistent clinical activity of tipifarnib in HNSCC patients with HRAS mutations is very encouraging,” said Antonio Gualberto, M.D., Ph.D., chief medical officer of Kura Oncology. “Based on these positive results, we continue to explore available options to rapidly advance the development of tipifarnib and subject to input from regulatory authorities, we plan to initiate a registration-enabling study in HRAS mutant HNSCC in 2018.”

About HRAS Mutant HNSCC

Head and neck cancer is one of the leading causes of cancer-related deaths worldwide, with squamous cell carcinomas accounting for most head and neck cancers. Response rates for the three agents approved for treatment of HNSCC in the second line, including cetuximab and immune therapy agents, are in the range of 13-16%, and median overall survival is up to 7.5 months. HRAS is a proto-oncogene that has been implicated in the development and progression of HNSCC and has been established to be uniquely farnesylated.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.

Forward-Looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of tipifarnib, progress and expected timing of Kura Oncology’s drug development programs and clinical trials and plans regarding future clinical trials and development activities. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura Oncology may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise, ” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura Oncology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Kura Oncology, Inc.

Posted: October 2017

Tagged with:

About author

Related Articles